{
  "report_rows": [
    {
      "kpi": "Total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$20.90B vs. cons $20.62B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$6.80 vs. cons $6.68",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Tirzepatide franchise revenue",
      "prediction": "BEAT",
      "answer": "pred ~$13.25B vs. cons $13.03B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 revenue",
      "prediction": "LOWER",
      "answer": "guide $82.0B-$85.0B vs. cons $85.38B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 non-GAAP EPS",
      "prediction": "BETTER",
      "answer": "guide $35.50-$37.00 vs. cons $34.83",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "H2 Foundayo / access trajectory",
      "prediction": "UNCHANGED",
      "answer": "guide broadly on-plan vs. cons UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -3.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 implicit H2 revenue concern outweighs a modest Q2 beat",
  "day5_confidence": "LOW"
}